NCT05753462 - Phase 1/2a for Safety, PK and PD of SQY51 in Paediatric and Adult Patients Duchenne Muscular Dystrophy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG

Phase 1, SQY51

SQY51 is administered by intravenous infusion.

DRUG

Phase 2a, SQY51 (cohort 1)

SQY51 is administered by intravenous infusion at dose 1

DRUG

Phase 2a, SQY51 (cohort 2)

SQY51 is administered by intravenous infusion at dose 2.

DRUG

Phase 2a, SQY51 (cohort 3)

SQY51 is administered by intravenous infusion at dose 3.

Trial Locations (1)

RECRUITING

Hôpital Raymond Poincaré, Garches